Biotech IV Monitor

ADPT — Adaptive Biotechnologies Corporation

$3.6B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Adaptive Biotechnologies Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$3.6B
Cash & investments$400Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-04

In progress, no date published

Phase 3 Modakafusp alfa (TAK-573)
Relapsed/Refractory Multiple Myeloma
date not published
Trial Planned

Cash position

Adaptive Biotechnologies Corporation reported $400M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $3M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow ADPT, you can start the conversation.
Track ADPT in real time
See live implied volatility for ADPT and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ADPT
Contact — questions or corrections about ADPT: dukeupt@gmail.com